Alaunos Therapeutics (TCRT) Preferred Stock Liabilities (2016 - 2018)

Alaunos Therapeutics has reported Preferred Stock Liabilities for 3 years, with the latest figure at $160.4 million in Q3 2018.

• For the quarter ending Q3 2018, Preferred Stock Liabilities rose 15.36% year-over-year to $160.4 million; the trailing twelve-month figure through Sep 2018 stood at $160.4 million (up 15.36% YoY), and the FY2017 full-year result was $144.0 million, up 14.9% from the prior year.
• Preferred Stock Liabilities for Q3 2018 stood at $160.4 million, up from $154.4 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $160.4 million in Q3 2018, with the low at $121.8 million in Q3 2016.
• Historically, Preferred Stock Liabilities has averaged $139.8 million across 3 years, with a median of $139.1 million in 2017.
• Annual changes were most pronounced in 2017 — Preferred Stock Liabilities climbed 14.16% — and 2018, when it grew 15.36%.
• Alaunos Therapeutics' Preferred Stock Liabilities stood at $125.3 million in 2016, then climbed by 14.9% to $144.0 million in 2017, then gained by 11.42% to $160.4 million in 2018.
• The last three Preferred Stock Liabilities figures came in at $160.4 million (Q3 2018), $154.4 million (Q2 2018), and $149.0 million (Q1 2018), per Business Quant data.